How much does MC2 Therapeutics Limited make?

MC2 Therapeutics Limited reported revenue of £18.3m and a loss of £221k in the year to 31 Dec 2025, according to its accounts filed at Companies House.

How many employees does MC2 Therapeutics Limited have?

MC2 Therapeutics Limited reported an average of 8 employees in the year to 31 Dec 2025.

Is MC2 Therapeutics Limited profitable?

No — MC2 Therapeutics Limited reported a loss of £221k in the year to 31 Dec 2025.

Company No. 05349119 · Incorporated 1 Feb 2005

MC2 Therapeutics Limited

Registered name: MC2 THERAPEUTICS LIMITED

Part of Mc2 Therapeutics A/S group

MC2 Therapeutics Limited made £18.3m revenue and a £221k loss in the year to 31 Dec 2025.

MC2 Therapeutics Limited’s revenue grew 16% to £18.3m in the year to 31 Dec 2025, with a loss of £221k and 8 employees. The company is classified under “manufacture of pharmaceutical preparations” and is based in Guildford; we hold 2 years of its filed accounts.

Full P&L filedSection C · ManufacturingSIC 21200Manufacture of pharmaceutical preparations SIC 72110Research and experimental development on biotechnology SIC 72190Other research and experimental development on natural sciences and engineering

Status: Active
Location: Guildford, South East
Age: 21 yrs · since 2005
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Small teamCapital-lightDoing more with less

Revenue

£18.3m

Growth ▲16.4%

Profit

−£221k

Growth —

Profit margin

−1.2%

Gross 39.7%

Employees

Change ▼42.9%

Profit / employee

−£27.6k

Revenue/employee £2.3m

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2024	31 Dec 2025
Disclosure	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£15.7m	£18.3m
Cost of sales	£8.2m	£11.1m
Gross profit	£7.5m	£7.3m
Operating profit	−£4.3m	£558k
Profit before tax	−£4.8m	−£223k
Profit after tax	−£4m	−£221k
Profit (best available)	−£4m	−£221k
Staff costs	£727k	£483k
Employees (average)	14	8
Ratios
Profit margin	−25.2%	−1.2%
Gross margin	48%	39.7%
Revenue per employee	£1.1m	£2.3m
Profit per employee	−£283k	−£27.6k
Growth (year on year)
Revenue growth	—	▲16.4%
Headcount growth	—	▼42.9%
Balance sheet — indirect signals, not revenue
Cash at bank	£940k	£1.9m
Net assets	−£4m	−£4.3m
Fixed assets	£583k	£478k
Current assets	£11.3m	£9.1m
Debtors	£5.6m	£4.3m
Deferred income	£2.3m	£913k
Source	FullAccounts · bulk data Jun 2026	FullAccounts · bulk data Jun 2026

Derived from the latest filing

How the business works

Profit margin: −1.2%; Profit ÷ revenue.
Gross margin: 39.7%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £2.3m; Revenue ÷ average employees.
Profit per employee: −£27.6k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 2.6%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 5%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 23.4%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£4.3m
Cash at bank: ▲98%; Now £1.9m
Headcount: ▼43%; Now 8
Deferred income: ▼61%; Now £913k
Fixed assets: ▼18%; Now £478k

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Mc2 Therapeutics A/S (registered outside the UK register)ultimate parent75–100%
MC2 Therapeutics Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Subsidiaries (1)

Disperse Pharma LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£221k), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.